West Pharmaceutical
374 hedge funds and large institutions have $8.59B invested in West Pharmaceutical in 2019 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 136 increasing their positions, 121 reducing their positions, and 42 closing their positions.
14% more capital invested
Capital invested by funds: $7.51B → $8.59B (+$1.07B)
12% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 121
2% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 42
0.7% more ownership
Funds ownership: 92.47% → 93.17% (+0.7%)
1% less funds holding
Funds holding: 379 → 374 (-5)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
90% less call options, than puts
Call options by funds: $5.02M | Put options by funds: $49.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
+$59.8M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$35.9M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$28.3M |
| 4 |
WCM Investment Management
Laguna Beach,
California
|
+$20.1M |
| 5 |
AAM
AMI Asset Management
Los Angeles,
California
|
+$19.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$24.5M |
| 2 |
Millennium Management
New York
|
-$23.6M |
| 3 |
Goldman Sachs
New York
|
-$17.6M |
| 4 |
Neuberger Berman Group
New York
|
-$15.5M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$14M |
WST Hedge Fund Activity: Q2 2019 in Review
374 of the 4,625 institutional investors tracked by Wall St. Rank reported a position in West Pharmaceutical (WST) for Q2 2019, worth a combined $8.59B — up 14% from $7.51B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new WST positions and 42 closed out — a net gain of 1 holder — while 136 added to existing stakes and 121 trimmed.
The largest buyer was Schroder Investment Management Group, adding an estimated $59.8M. The largest seller was Deutsche Bank, cutting an estimated $24.5M.
- 374 institutional investors held West Pharmaceutical (WST) as of Q2 2019, down from 379 in Q1 2019.
- Funds reported $8.59B of West Pharmaceutical stock for Q2 2019, up 14% quarter-over-quarter.
- 43 funds opened new West Pharmaceutical positions in Q2 2019 and 42 closed out, a net change of +1 holder.
- The largest West Pharmaceutical buyer in Q2 2019 was Schroder Investment Management Group, an estimated $59.8M added.
- The largest West Pharmaceutical seller in Q2 2019 was Deutsche Bank, an estimated $24.5M sold.
Based on aggregated 13F filings for Q2 2019.